Side-by-side · Research reference
HumaninvsVilon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BAnimal-StrongHUMAN-REVIEWED13/49 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
Vilon
Khavinson Bioregulator · Dipeptide
Literature lacks standardised clinical route
01Mechanism of Action
Parameter
Humanin
Vilon
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
Immune cell differentiation pathways, chromatin modification
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011Khavinson 2002Lezhava 2023
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Unknown — no HPA/HPG axis data
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
Vilon
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
Unknown — literature does not specify chronic administration protocols
Duration
8–12 weeks in animal studies
Not characterised in humans
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Standard dose
—
No clinical standard — literature lacks human dosing
Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.
Animal model dose
—
In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)
Not translatable to human mg/kg without pharmacokinetic data.
Route
—
Likely SQ or oral (Khavinson school uses both); no published ROA validation
Half-life
—
Not published — dipeptides typically <10 min plasma t½
03Metabolic / Fat Loss Evidence
Parameter
Humanin
Vilon
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
Vilon
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
Absent from PubMed-indexed literature
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
—
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
Theoretical risk
—
Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)
Antibody formation
—
Not reported; dipeptides generally low immunogenicity
Animal models
—
No adverse effects noted in mouse thymocyte or pineal lymphoid cultures
Absolute Contraindications
Humanin
- ·Unknown — no human data
Vilon
- ·Active autoimmune disease (theoretical — no clinical data)
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
Vilon
- ·Pregnancy / lactation (no safety data)
- ·Acute infection with cytokine storm risk (immune modulation unknown)
05Administration Protocol
Parameter
Humanin
Vilon
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Likely lyophilised powder, refrigerated. Reconstitution protocols not published.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
—
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
Vilon
+ Epitalon
ModerateBoth are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.
- Vilon
- Empirical — no standard
- Epitalon
- Empirical — often 10 mg cycles
- Frequency
- Sequential or concurrent (literature ambiguous)
- Primary benefit
- Multi-system aging modulation (immune + pineal/circadian)
+ Thymalin
WeakThymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.
- Vilon
- No standard
- Thymalin
- 10–100 mg IM (polypeptide complex)
- Primary benefit
- Redundant — both target T-cell differentiation